Circulating tumor cells as a surrogate marker for determining clinical outcome to mFOLFOX chemotherapy in patients with stage III colon cancer

BACKGROUND: This study was aimed to detect post-chemotherapeutic circulating tumour cells (CTCs) in stage III colon cancer patients and identify those who were at high risk of relapse. METHODS: We used human telomerase reverse transcriptase, cytokeratin-19, cytokeratin-20, and carcinoembryonic antig...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, C-Y, Tsai, H-L, Uen, Y-H, Hu, H-M, Chen, C-W, Cheng, T-L, Lin, S-R, Wang, J-Y
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3590657/
https://www.ncbi.nlm.nih.gov/pubmed/23422758
http://dx.doi.org/10.1038/bjc.2012.595

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3590657/
https://www.ncbi.nlm.nih.gov/pubmed/23422758
http://dx.doi.org/10.1038/bjc.2012.595

Ejemplares similares